1887
Research Open Access
Like 0

Abstract

Background

Recent and reliable estimates on the prevalence of coinfection with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) in Europe are lacking.

Aim

Leveraged on a study designed to assess HIV/HCV coinfection prevalence, we assessed the prevalence of HIV/HBV coinfection in Spain in 2018 and compared the results with five similar studies performed since 2002.

Methods

This cross-sectional prevalence study was carried out in 43 centres, and patients were selected using simple random sampling. The reference population comprised 40,322 patients and the sample size were 1,690 patients.

Results

The prevalence of HIV/HBV coinfection in Spain at the end of 2018 was 3.2%. The prevalence in 2002, 2009, 2015, 2016 and 2017 was 4.9%, 3.4%, 3%, 3.9% and 3%, respectively. Among the HIV/HBV-coinfected patients identified in 2018, 16.7% had cirrhosis according to transient elastography and 26.3% tested positive for antibodies against hepatitis D virus. All HIV/HBV-coinfected patients were receiving drugs with activity against HBV, and 97% of those tested for HBV DNA had an HBV DNA load < 80 IU/mL.

Conclusions

The prevalence of HIV/HBV coinfection in Spain remained stable at around 3% for a decade. Our data could facilitate the design of national programmes to control HBV infection and help identify areas of patient management that need improvement.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2021.26.25.2000236
2021-06-24
2021-10-27
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2021.26.25.2000236
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/26/25/eurosurv-26-25-4.html?itemId=/content/10.2807/1560-7917.ES.2021.26.25.2000236&mimeType=html&fmt=ahah

References

  1. Singh KP, Crane M, Audsley J, Avihingsanon A, Sasadeusz J, Lewin SR. HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment. AIDS. 2017;31(15):2035-52.  https://doi.org/10.1097/QAD.0000000000001574  PMID: 28692539 
  2. Thornton AC, Jose S, Bhagani S, Chadwick D, Dunn D, Gilson R, et al. Hepatitis B, hepatitis C, and mortality among HIV-positive individuals. AIDS. 2017;31(18):2525-32.  https://doi.org/10.1097/QAD.0000000000001646  PMID: 28926400 
  3. Kouamé GM, Boyd A, Moh R, Badje A, Gabillard D, Ouattara E, et al. Higher mortality despite early antiretroviral therapy in human immunodeficiency virus and hepatitis B virus (HBV)-coinfected patients with high HBV replication. Clin Infect Dis. 2018;66(1):112-20.  https://doi.org/10.1093/cid/cix747  PMID: 29020361 
  4. Christian B, Fabian E, Macha I, Mpangala S, Thio CL, Ulenga N, et al. Hepatitis B virus coinfection is associated with high early mortality in HIV-infected Tanzanians on antiretroviral therapy. AIDS. 2019;33(3):465-73.  https://doi.org/10.1097/QAD.0000000000002073  PMID: 30702515 
  5. Kourtis AP, Bulterys M, Hu DJ, Jamieson DJ. HIV-HBV coinfection--a global challenge. N Engl J Med. 2012;366(19):1749-52.  https://doi.org/10.1056/NEJMp1201796  PMID: 22571198 
  6. Mason LM, Duffell E, Veldhuijzen IK, Petriti U, Bunge EM, Tavoschi L. Hepatitis B and C prevalence and incidence in key population groups with multiple risk factors in the EU/EEA: a systematic review. Euro Surveill. 2019;24(30):1800614.  https://doi.org/10.2807/1560-7917.ES.2019.24.30.1800614  PMID: 31362808 
  7. World Health Organization (WHO). Global Hepatitis Report, 2017. Geneva: WHO; 2017. Available from: http://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-eng.pdf?sequence=1
  8. Bollinger RC, Thio CL, Sulkowski MS, McKenzie-White J, Thomas DL, Flexner C. Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV. Lancet HIV. 2020;7(6):e443-8.  https://doi.org/10.1016/S2352-3018(19)30342-X  PMID: 31870675 
  9. Berenguer J, Jarrín I, Pérez-Latorre L, Hontañón V, Vivancos MJ, Navarro J, et al. human immunodeficiency virus/hepatits C virus coinfection in Spain: elimination is feasible, but the burden of residual cirrhosis will be significant. Open Forum Infect Dis. 2018;5(1):ofx258.  https://doi.org/10.1093/ofid/ofx258  PMID: 29354658 
  10. Fanciulli C, Berenguer J, Busca C, Vivancos MJ, Domingez L, Navarro J, et al. HIV/HCV coinfection in Spain: moving fast towards elimination. Abstract # OR-14. X Congreso Nacional GESIDA; 6-9 Nov 2018, Madrid, Spain. Available from: http://2018.congresogesida.es/images/site/ponencias/Dia3_Jueves8/OR-09_OR-16_Auditorio/OR-14.pdf
  11. Pérez-Latorre L, Berenguer J, Micán R, Montero M, Cifuentes C, Puig T, et al. HIV/HBV coinfection in Spain: temporal trends and patient characteristics (GESIDA 8514 study group). P-029. X Congreso Nacional GESIDA; 6-9 Nov 2018; Madrid, Spain. Available from: http://2018.congresogesida.es/images/site/Revista_GESIDA_2018_web.pdf
  12. World Medical Association (WMA). WMA Declaration of Helsinki – ethical principles for medical research involving human subjects. Ferney-Voltaire: WMA; 2018. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects
  13. Centers for Disease Control and Prevention. From the Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA. 1993;269(6):729-30.  https://doi.org/10.1001/jama.1993.03500060023008  PMID: 8093740 
  14. European AIDS Clinical Society (EACS). Guidelines version 10.0 November 2019. Brussels: EACS; 2019. Available from: https://www.eacsociety.org/files/2019_guidelines-10.0_final.pdf
  15. Calleja-Panero JL, Llop-Herrera E, Ruiz-Moraga M, de-la-Revilla-Negro J, Calvo-Bonacho E, Pons-Renedo F, et al. Prevalence of viral hepatitis (B and C) serological markers in healthy working population. Rev Esp Enferm Dig. 2013;105(5):249-54.  https://doi.org/10.4321/S1130-01082013000500002  PMID: 23971655 
  16. Muñoz-Gámez JA, Salmerón J. Prevalence of hepatitis B and C in Spain - further data are needed. Rev Esp Enferm Dig. 2013;105(5):245-8.  https://doi.org/10.4321/S1130-01082013000500001  PMID: 23971654 
  17. Fanciulli C, Berenguer J, Busca C, Del Campo S, Domingez L, Navarro J, et al. HIV/HCV coinfection in Spain: Trouble will soon be over. PE37/10. 17th European Aids Conference (EACS); 6-9 Nov 2019; Basel, Switzerland.
  18. Arístegui Fernández J, Díez-Domingo J, Marés Bermúdez J, Martinón Torres F. [Vaccination against hepatitis B. Impact of vaccination programmes after 20 years of use in Spain. Is it time for a change?]. Enferm Infecc Microbiol Clin. 2015;33(2):113-8. Spanish. PMID: 25620127 
  19. Heuft MM, Houba SM, van den Berk GE, Smissaert van de Haere T, van Dam AP, Dijksman LM, et al. Protective effect of hepatitis B virus-active antiretroviral therapy against primary hepatitis B virus infection. AIDS. 2014;28(7):999-1005.  https://doi.org/10.1097/QAD.0000000000000180  PMID: 24685742 
  20. Gatanaga H, Hayashida T, Tanuma J, Oka S. Prophylactic effect of antiretroviral therapy on hepatitis B virus infection. Clin Infect Dis. 2013;56(12):1812-9.  https://doi.org/10.1093/cid/cit145  PMID: 23487374 
  21. Centro Nacional de Epidemiología-Instituto de Salud Carlos III/ Plan Nacional sobre el Sida-S.G. de Promoción de la salud y Vigilancia en Salud Pública. Encuesta Hospitalaria de Pacientes con VIH/sida. Resultados 2017. Análisis de la evolución 2002-2017. [Hospital survey of patients with HIV/AIDS Results 2017. Analysis of the development 2002-2017. Madrid: Instituto de Salud Carlos III; 2018. Spanish. Available from: https://www.mscbs.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/vigilancia/InformeEncuestaHospitalaria2017_def.pdf
  22. Aguilera A, Trastoy R, Rodríguez-Calviño J, Manso T, de Mendoza C, Soriano V. Prevalence and incidence of hepatitis delta in patients with chronic hepatitis B in Spain. Eur J Gastroenterol Hepatol. 2018;30(9):1060-2.  https://doi.org/10.1097/MEG.0000000000001163  PMID: 29742524 
  23. Soriano V, Grint D, d’Arminio Monforte A, Horban A, Leen C, Poveda E, et al. Hepatitis delta in HIV-infected individuals in Europe. AIDS. 2011;25(16):1987-92.  https://doi.org/10.1097/QAD.0b013e32834babb3  PMID: 21857493 
  24. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284(4):450-6.  https://doi.org/10.1001/jama.284.4.450  PMID: 10904508 
  25. Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz B, Chaplinskas S, et al. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis. 2008;198(9):1337-44.  https://doi.org/10.1086/592171  PMID: 18767985 
  26. Islam N, Krajden M, Gilbert M, Gustafson P, Yu A, Kuo M, et al. Role of primary T-cell immunodeficiency and hepatitis B coinfection on spontaneous clearance of hepatitis C: The BC Hepatitis Testers Cohort. J Viral Hepat. 2017;24(5):421-9.  https://doi.org/10.1111/jvh.12650  PMID: 27885757 
  27. Mavilia MG, Wu GY. HBV-HCV coinfection: viral interactions, management, and viral reactivation. J Clin Transl Hepatol. 2018;6(3):296-305.  https://doi.org/10.14218/JCTH.2018.00016  PMID: 30271742 
  28. Liaw YF, Yeh CT, Tsai SL. Impact of acute hepatitis B virus superinfection on chronic hepatitis C virus infection. Am J Gastroenterol. 2000;95(10):2978-80.  https://doi.org/10.1111/j.1572-0241.2000.02337.x  PMID: 11051381 
/content/10.2807/1560-7917.ES.2021.26.25.2000236
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error